{"id":"https://openalex.org/W7224133708","doi":"https://doi.org/10.1142/s1793524526501317","title":"Mathematical modeling and efficacy analysis of dual immune checkpoint blockade in breast cancer: Combination therapy with anti-PD-L1 and anti-CTLA-4","display_name":"Mathematical modeling and efficacy analysis of dual immune checkpoint blockade in breast cancer: Combination therapy with anti-PD-L1 and anti-CTLA-4","publication_year":2026,"publication_date":"2026-10-28","ids":{"openalex":"https://openalex.org/W7224133708","doi":"https://doi.org/10.1142/s1793524526501317"},"language":"en","primary_location":{"id":"doi:10.1142/s1793524526501317","doi":"https://doi.org/10.1142/s1793524526501317","is_oa":false,"landing_page_url":"https://doi.org/10.1142/s1793524526501317","pdf_url":null,"source":{"id":"https://openalex.org/S197333199","display_name":"International Journal of Biomathematics","issn_l":"1793-5245","issn":["1793-5245","1793-7159"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","norway-1","poland-40","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319815","host_organization_name":"World Scientific","host_organization_lineage":["https://openalex.org/P4310319815"],"host_organization_lineage_names":["World Scientific"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Biomathematics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5160050695","display_name":"Zhifei Wei","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zhifei Wei","raw_affiliation_strings":[""],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5125247020","display_name":"Chenghang Li","orcid":"https://orcid.org/0009-0008-4290-221X","observed_orcids":["https://orcid.org/0009-0008-4290-221X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chenghang Li","raw_affiliation_strings":[""],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021871320","display_name":"Jinzhi Lei","orcid":"https://orcid.org/0000-0002-2670-6760","observed_orcids":["https://orcid.org/0000-0002-2670-6760"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jinzhi Lei","raw_affiliation_strings":["https://orcid.org/0000-0002-2670-6760"],"raw_orcid":"https://orcid.org/0000-0002-2670-6760","affiliations":[{"raw_affiliation_string":"https://orcid.org/0000-0002-2670-6760","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.83538548,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8773999810218811,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8773999810218811,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11829","display_name":"Mathematical Biology Tumor Growth","score":0.12080000340938568,"subfield":{"id":"https://openalex.org/subfields/2611","display_name":"Modeling and Simulation"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dual-immune-checkpoint-blockade","display_name":"dual immune checkpoint blockade","score":0.968999981880188},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.9179999828338623},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.9860000014305115},{"id":"https://openalex.org/keywords/anti-ctla-4","display_name":"anti-CTLA-4","score":0.9990000128746033},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.6850000023841858},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.6940000057220459},{"id":"https://openalex.org/keywords/multiscale-mathematical-model","display_name":"multiscale mathematical model","score":0.7720000147819519},{"id":"https://openalex.org/keywords/dosing-schedule-optimization","display_name":"dosing schedule optimization","score":0.8619999885559082},{"id":"https://openalex.org/keywords/sequential-administration","display_name":"sequential administration","score":0.527999997138977},{"id":"https://openalex.org/keywords/t-cell-exhaustion","display_name":"T cell exhaustion","score":0.7490000128746033},{"id":"https://openalex.org/keywords/pd-1-pd-l1-signaling","display_name":"PD-1/PD-L1 signaling","score":0.8550000190734863},{"id":"https://openalex.org/keywords/cytokine-signaling","display_name":"cytokine signaling","score":0.8009999990463257},{"id":"https://openalex.org/keywords/receptor-ligand-binding-kinetics","display_name":"receptor-ligand binding kinetics","score":0.9599999785423279},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7329999804496765},{"id":"https://openalex.org/keywords/immune-evasion","display_name":"immune evasion","score":0.6510000228881836},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.8790000081062317}],"concepts":[{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5812000036239624},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.5710999965667725},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5181999802589417},{"id":"https://openalex.org/C51785407","wikidata":"https://www.wikidata.org/wiki/Q2627568","display_name":"Effector","level":2,"score":0.5116999745368958},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.47699999809265137},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.44510000944137573},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.4447999894618988},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.43050000071525574},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.4296000003814697},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.41690000891685486},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.39100000262260437},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.3732999861240387},{"id":"https://openalex.org/C68387754","wikidata":"https://www.wikidata.org/wiki/Q7271585","display_name":"Schedule","level":2,"score":0.32010000944137573},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.3147999942302704},{"id":"https://openalex.org/C2780980858","wikidata":"https://www.wikidata.org/wiki/Q110022","display_name":"Dual (grammatical number)","level":2,"score":0.3093000054359436},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.29670000076293945},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.28790000081062317},{"id":"https://openalex.org/C2776187077","wikidata":"https://www.wikidata.org/wiki/Q1888235","display_name":"Mammary tumor","level":4,"score":0.2831999957561493},{"id":"https://openalex.org/C2776217527","wikidata":"https://www.wikidata.org/wiki/Q944828","display_name":"Sensitization","level":2,"score":0.2768000066280365},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.2759000062942505},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2718999981880188},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2651999890804291},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.2578999996185303},{"id":"https://openalex.org/C2779341262","wikidata":"https://www.wikidata.org/wiki/Q182581","display_name":"Immunity","level":3,"score":0.2554999887943268},{"id":"https://openalex.org/C2778112365","wikidata":"https://www.wikidata.org/wiki/Q3511065","display_name":"Sequence (biology)","level":2,"score":0.2526000142097473}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1142/s1793524526501317","doi":"https://doi.org/10.1142/s1793524526501317","is_oa":false,"landing_page_url":"https://doi.org/10.1142/s1793524526501317","pdf_url":null,"source":{"id":"https://openalex.org/S197333199","display_name":"International Journal of Biomathematics","issn_l":"1793-5245","issn":["1793-5245","1793-7159"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","norway-1","poland-40","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319815","host_organization_name":"World Scientific","host_organization_lineage":["https://openalex.org/P4310319815"],"host_organization_lineage_names":["World Scientific"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Biomathematics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2429444364","https://openalex.org/W7212161602","https://openalex.org/W3005824507","https://openalex.org/W2945644530","https://openalex.org/W3187303418","https://openalex.org/W4404863401","https://openalex.org/W2478486416","https://openalex.org/W4413889196","https://openalex.org/W4296177499","https://openalex.org/W4405316583"],"abstract_inverted_index":{"Combination":[0],"immunotherapy":[1],"targeting":[2],"PD-L1":[3,65,114],"and":[4,45,100,113,149,168,191],"CTLA-4":[5,58,123],"has":[6],"emerged":[7],"as":[8],"a":[9,55,76,180],"promising":[10],"strategy":[11],"in":[12],"treating":[13],"breast":[14],"cancer.":[15],"However,":[16],"identifying":[17],"an":[18],"optimal":[19],"dosing":[20,137,150],"schedule":[21],"remains":[22],"challenging":[23],"due":[24],"to":[25,84,195],"nonlinear":[26],"dynamics":[27],"within":[28,54],"the":[29,37,42,86,116,126,129,184],"tumor":[30,171],"microenvironment":[31],"(TME).":[32],"While":[33],"preclinical":[34],"experiments":[35],"demonstrate":[36],"synergy":[38],"of":[39,48,111,119,128,136,187],"dual":[40,188],"blockade,":[41],"distinct":[43],"functional":[44],"temporal":[46],"roles":[47],"these":[49,90],"checkpoints":[50],"are":[51],"rarely":[52],"quantified":[53],"unified":[56],"framework:":[57],"regulates":[59],"early":[60],"T":[61,68,131],"cell":[62,69,132],"priming,":[63],"whereas":[64,122],"promotes":[66],"effector":[67],"exhaustion.":[70],"In":[71],"this":[72],"study,":[73],"we":[74],"develop":[75],"multiscale":[77],"mathematical":[78],"model":[79,94],"calibrated":[80],"against":[81],"experimental":[82],"data":[83],"characterize":[85],"dynamic":[87],"interactions":[88],"between":[89],"two":[91],"pathways.":[92],"The":[93],"integrates":[95],"drug":[96],"pharmacokinetics,":[97],"cytokine":[98],"signaling,":[99],"receptor-ligand":[101],"binding":[102],"kinetics.":[103],"Model":[104],"analyses":[105],"indicate":[106],"that":[107,140],"coordinated":[108],"high":[109],"expression":[110],"PD-1":[112],"is":[115],"major":[117],"driver":[118],"immune":[120],"escape,":[121],"primarily":[124],"constrains":[125],"magnitude":[127],"initial":[130],"response.":[133],"Furthermore,":[134],"optimization":[135],"schedules":[138],"reveals":[139],"therapeutic":[141],"efficacy":[142],"critically":[143],"depends":[144],"on":[145],"both":[146],"administration":[147,154],"sequence":[148],"intervals.":[151],"Specifically,":[152],"sequential":[153],"initiating":[155],"with":[156,174],"anti-CTLA-4":[157],"followed":[158],"by":[159],"anti-PD-L1":[160],"at":[161],"shorter":[162],"intervals":[163],"markedly":[164],"enhances":[165],"antitumor":[166],"immunity":[167],"achieves":[169],"superior":[170],"regression":[172],"compared":[173],"concurrent":[175],"dosing.":[176],"This":[177],"study":[178],"establishes":[179],"quantitative":[181],"framework":[182],"for":[183],"rational":[185],"design":[186],"checkpoint":[189],"blockade":[190],"provides":[192],"predictive":[193],"insights":[194],"guide":[196],"clinical":[197],"protocol":[198],"optimization.":[199]},"counts_by_year":[],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2026-10-29T00:00:00"}